COVID-19 Impact on Global NSCLS Drugs Market Size, Status and Forecast 2020-2026

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered: Ranking by NSCLS Drugs Revenue
• 1.4 Market Analysis by Type
  • 1.4.1 Global NSCLS Drugs Market Size Growth Rate by Type: 2020 VS 2026
  • 1.4.2 EGFR Targeting
  • 1.4.3 ALK Targeting
  • 1.4.4 PD-1/PD-L1 Targeting
  • 1.4.5 Gemcitabine
  • 1.4.6 Cisplatin/Carboplatin
  • 1.4.7 Pemetrexed
  • 1.4.8 Paclitaxel
  • 1.4.9 Others
• 1.5 Market by Application
  • 1.5.1 Global NSCLS Drugs Market Share by Application: 2020 VS 2026
  • 1.5.2 ≤ 30 Years Old
  • 1.5.3 31 - 45 Years Old
  • 1.5.4 46 - 60 Years Old
  • 1.5.5 ＞ 60 Years Old
• 1.6 Coronavirus Disease 2019 (Covid-19): NSCLS Drugs Industry Impact
  • 1.6.1 How the Covid-19 is Affecting the NSCLS Drugs Industry
    • 1.6.1.1 NSCLS Drugs Business Impact Assessment - Covid-19
    • 1.6.1.2 Supply Chain Challenges
    • 1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
  • 1.6.2 Market Trends and NSCLS Drugs Potential Opportunities in the COVID-19 Landscape
  • 1.6.3 Measures / Proposal against Covid-19
    • 1.6.3.1 Government Measures to Combat Covid-19 Impact
    • 1.6.3.2 Proposal for NSCLS Drugs Players to Combat Covid-19 Impact
• 1.7 Study Objectives
• 1.8 Years Considered

2 Global Growth Trends by Regions

• 2.1 NSCLS Drugs Market Perspective (2015-2026)
• 2.2 NSCLS Drugs Growth Trends by Regions
  • 2.2.1 NSCLS Drugs Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 NSCLS Drugs Historic Market Share by Regions (2015-2020)
  • 2.2.3 NSCLS Drugs Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis
  • 2.3.5 NSCLS Drugs Market Growth Strategy
  • 2.3.6 Primary Interviews with Key NSCLS Drugs Players (Opinion Leaders)

3 Competition Landscape by Key Players

• 3.1 Global Top NSCLS Drugs Players by Market Size
  • 3.1.1 Global Top NSCLS Drugs Players by Revenue (2015-2020)
  • 3.1.2 Global NSCLS Drugs Revenue Market Share by Players (2015-2020)
  • 3.1.3 Global NSCLS Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.2 Global NSCLS Drugs Market Concentration Ratio
  • 3.2.1 Global NSCLS Drugs Market Concentration Ratio (CR5 and HHI)
  • 3.2.2 Global Top 10 and Top 5 Companies by NSCLS Drugs Revenue in 2019
• 3.3 NSCLS Drugs Key Players Head office and Area Served
• 3.4 Key Players NSCLS Drugs Product Solution and Service
• 3.5 Date of Enter into NSCLS Drugs Market
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

• 4.1 Global NSCLS Drugs Historic Market Size by Type (2015-2020)
• 4.2 Global NSCLS Drugs Forecasted Market Size by Type (2021-2026)

5 NSCLS Drugs Breakdown Data by Application (2015-2026)

• 5.1 Global NSCLS Drugs Market Size by Application (2015-2020)
• 5.2 Global NSCLS Drugs Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America NSCLS Drugs Market Size (2015-2020)
• 6.2 NSCLS Drugs Key Players in North America (2019-2020)
• 6.3 North America NSCLS Drugs Market Size by Type (2015-2020)
• 6.4 North America NSCLS Drugs Market Size by Application (2015-2020)

7 Europe

• 7.1 Europe NSCLS Drugs Market Size (2015-2020)
• 7.2 NSCLS Drugs Key Players in Europe (2019-2020)
• 7.3 Europe NSCLS Drugs Market Size by Type (2015-2020)
• 7.4 Europe NSCLS Drugs Market Size by Application (2015-2020)

8 China

• 8.1 China NSCLS Drugs Market Size (2015-2020)
• 8.2 NSCLS Drugs Key Players in China (2019-2020)
• 8.3 China NSCLS Drugs Market Size by Type (2015-2020)
• 8.4 China NSCLS Drugs Market Size by Application (2015-2020)

9 Japan

• 9.1 Japan NSCLS Drugs Market Size (2015-2020)
• 9.2 NSCLS Drugs Key Players in Japan (2019-2020)
• 9.3 Japan NSCLS Drugs Market Size by Type (2015-2020)
• 9.4 Japan NSCLS Drugs Market Size by Application (2015-2020)

10 Southeast Asia

• 10.1 Southeast Asia NSCLS Drugs Market Size (2015-2020)
• 10.2 NSCLS Drugs Key Players in Southeast Asia (2019-2020)
• 10.3 Southeast Asia NSCLS Drugs Market Size by Type (2015-2020)
• 10.4 Southeast Asia NSCLS Drugs Market Size by Application (2015-2020)

11 India

• 11.1 India NSCLS Drugs Market Size (2015-2020)
• 11.2 NSCLS Drugs Key Players in India (2019-2020)
• 11.3 India NSCLS Drugs Market Size by Type (2015-2020)
• 11.4 India NSCLS Drugs Market Size by Application (2015-2020)

12 Central & South America

• 12.1 Central & South America NSCLS Drugs Market Size (2015-2020)
• 12.2 NSCLS Drugs Key Players in Central & South America (2019-2020)
• 12.3 Central & South America NSCLS Drugs Market Size by Type (2015-2020)
• 12.4 Central & South America NSCLS Drugs Market Size by Application (2015-2020)

13 Key Players Profiles

• 13.1 Roche
  • 13.1.1 Roche Company Details
  • 13.1.2 Roche Business Overview and Its Total Revenue
  • 13.1.3 Roche NSCLS Drugs Introduction
  • 13.1.4 Roche Revenue in NSCLS Drugs Business (2015-2020))
  • 13.1.5 Roche Recent Development
• 13.2 Novartis
  • 13.2.1 Novartis Company Details
  • 13.2.2 Novartis Business Overview and Its Total Revenue
  • 13.2.3 Novartis NSCLS Drugs Introduction
  • 13.2.4 Novartis Revenue in NSCLS Drugs Business (2015-2020)
  • 13.2.5 Novartis Recent Development
• 13.3 Pfizer
  • 13.3.1 Pfizer Company Details
  • 13.3.2 Pfizer Business Overview and Its Total Revenue
  • 13.3.3 Pfizer NSCLS Drugs Introduction
  • 13.3.4 Pfizer Revenue in NSCLS Drugs Business (2015-2020)
  • 13.3.5 Pfizer Recent Development
• 13.4 Merck
  • 13.4.1 Merck Company Details
  • 13.4.2 Merck Business Overview and Its Total Revenue
  • 13.4.3 Merck NSCLS Drugs Introduction
  • 13.4.4 Merck Revenue in NSCLS Drugs Business (2015-2020)
  • 13.4.5 Merck Recent Development
• 13.5 Bristol-Myers Squibb
  • 13.5.1 Bristol-Myers Squibb Company Details
  • 13.5.2 Bristol-Myers Squibb Business Overview and Its Total Revenue
  • 13.5.3 Bristol-Myers Squibb NSCLS Drugs Introduction
  • 13.5.4 Bristol-Myers Squibb Revenue in NSCLS Drugs Business (2015-2020)
  • 13.5.5 Bristol-Myers Squibb Recent Development
• 13.6 Eli Lilly and Company
  • 13.6.1 Eli Lilly and Company Company Details
  • 13.6.2 Eli Lilly and Company Business Overview and Its Total Revenue
  • 13.6.3 Eli Lilly and Company NSCLS Drugs Introduction
  • 13.6.4 Eli Lilly and Company Revenue in NSCLS Drugs Business (2015-2020)
  • 13.6.5 Eli Lilly and Company Recent Development
• 13.7 Takeda Pharmaceutical
  • 13.7.1 Takeda Pharmaceutical Company Details
  • 13.7.2 Takeda Pharmaceutical Business Overview and Its Total Revenue
  • 13.7.3 Takeda Pharmaceutical NSCLS Drugs Introduction
  • 13.7.4 Takeda Pharmaceutical Revenue in NSCLS Drugs Business (2015-2020)
  • 13.7.5 Takeda Pharmaceutical Recent Development
• 13.8 Boehringer-Ingelheim
  • 13.8.1 Boehringer-Ingelheim Company Details
  • 13.8.2 Boehringer-Ingelheim Business Overview and Its Total Revenue
  • 13.8.3 Boehringer-Ingelheim NSCLS Drugs Introduction
  • 13.8.4 Boehringer-Ingelheim Revenue in NSCLS Drugs Business (2015-2020)
  • 13.8.5 Boehringer-Ingelheim Recent Development
• 13.9 AstraZeneca
  • 13.9.1 AstraZeneca Company Details
  • 13.9.2 AstraZeneca Business Overview and Its Total Revenue
  • 13.9.3 AstraZeneca NSCLS Drugs Introduction
  • 13.9.4 AstraZeneca Revenue in NSCLS Drugs Business (2015-2020)
  • 13.9.5 AstraZeneca Recent Development
• 13.10 Betta Pharmaceuticals
  • 13.10.1 Betta Pharmaceuticals Company Details
  • 13.10.2 Betta Pharmaceuticals Business Overview and Its Total Revenue
  • 13.10.3 Betta Pharmaceuticals NSCLS Drugs Introduction
  • 13.10.4 Betta Pharmaceuticals Revenue in NSCLS Drugs Business (2015-2020)
  • 13.10.5 Betta Pharmaceuticals Recent Development
• 13.11 Qilu Oharmaceutical
  • 10.11.1 Qilu Oharmaceutical Company Details
  • 10.11.2 Qilu Oharmaceutical Business Overview and Its Total Revenue
  • 10.11.3 Qilu Oharmaceutical NSCLS Drugs Introduction
  • 10.11.4 Qilu Oharmaceutical Revenue in NSCLS Drugs Business (2015-2020)
  • 10.11.5 Qilu Oharmaceutical Recent Development
• 13.12 Pierre Fabre Medicament
  • 10.12.1 Pierre Fabre Medicament Company Details
  • 10.12.2 Pierre Fabre Medicament Business Overview and Its Total Revenue
  • 10.12.3 Pierre Fabre Medicament NSCLS Drugs Introduction
  • 10.12.4 Pierre Fabre Medicament Revenue in NSCLS Drugs Business (2015-2020)
  • 10.12.5 Pierre Fabre Medicament Recent Development
• 13.13 Chemo Wanbang Biopharma
  • 10.13.1 Chemo Wanbang Biopharma Company Details
  • 10.13.2 Chemo Wanbang Biopharma Business Overview and Its Total Revenue
  • 10.13.3 Chemo Wanbang Biopharma NSCLS Drugs Introduction
  • 10.13.4 Chemo Wanbang Biopharma Revenue in NSCLS Drugs Business (2015-2020)
  • 10.13.5 Chemo Wanbang Biopharma Recent Development
• 13.14 Hetero Drugs
  • 10.14.1 Hetero Drugs Company Details
  • 10.14.2 Hetero Drugs Business Overview and Its Total Revenue
  • 10.14.3 Hetero Drugs NSCLS Drugs Introduction
  • 10.14.4 Hetero Drugs Revenue in NSCLS Drugs Business (2015-2020)
  • 10.14.5 Hetero Drugs Recent Development
• 13.15 Harbin Gloria Pharmaceuticals
  • 10.15.1 Harbin Gloria Pharmaceuticals Company Details
  • 10.15.2 Harbin Gloria Pharmaceuticals Business Overview and Its Total Revenue
  • 10.15.3 Harbin Gloria Pharmaceuticals NSCLS Drugs Introduction
  • 10.15.4 Harbin Gloria Pharmaceuticals Revenue in NSCLS Drugs Business (2015-2020)
  • 10.15.5 Harbin Gloria Pharmaceuticals Recent Development
• 13.16 Luoxin Pharmaceutical
  • 10.16.1 Luoxin Pharmaceutical Company Details
  • 10.16.2 Luoxin Pharmaceutical Business Overview and Its Total Revenue
  • 10.16.3 Luoxin Pharmaceutical NSCLS Drugs Introduction
  • 10.16.4 Luoxin Pharmaceutical Revenue in NSCLS Drugs Business (2015-2020)
  • 10.16.5 Luoxin Pharmaceutical Recent Development
• 13.17 Teva Pharmaceutical
  • 10.17.1 Teva Pharmaceutical Company Details
  • 10.17.2 Teva Pharmaceutical Business Overview and Its Total Revenue
  • 10.17.3 Teva Pharmaceutical NSCLS Drugs Introduction
  • 10.17.4 Teva Pharmaceutical Revenue in NSCLS Drugs Business (2015-2020)
  • 10.17.5 Teva Pharmaceutical Recent Development
• 13.18 Mylan
  • 10.18.1 Mylan Company Details
  • 10.18.2 Mylan Business Overview and Its Total Revenue
  • 10.18.3 Mylan NSCLS Drugs Introduction
  • 10.18.4 Mylan Revenue in NSCLS Drugs Business (2015-2020)
  • 10.18.5 Mylan Recent Development
• 13.19 Sun Pharmaceutical
  • 10.19.1 Sun Pharmaceutical Company Details
  • 10.19.2 Sun Pharmaceutical Business Overview and Its Total Revenue
  • 10.19.3 Sun Pharmaceutical NSCLS Drugs Introduction
  • 10.19.4 Sun Pharmaceutical Revenue in NSCLS Drugs Business (2015-2020)
  • 10.19.5 Sun Pharmaceutical Recent Development
• 13.20 Fosun Pharma
  • 10.20.1 Fosun Pharma Company Details
  • 10.20.2 Fosun Pharma Business Overview and Its Total Revenue
  • 10.20.3 Fosun Pharma NSCLS Drugs Introduction
  • 10.20.4 Fosun Pharma Revenue in NSCLS Drugs Business (2015-2020)
  • 10.20.5 Fosun Pharma Recent Development

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Disclaimer